Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Lewis, D. A. Articles by Montrose, D. Search for Related Content PubMed Citation Articles by Lewis, D. A. Articles by Montrose, D. Schizophrenia Spectrum Disorders

Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia

OBJECTIVE: Deficits in working memory and cognitive control in schizophrenia are associated with impairments in prefrontal cortical function, including altered gamma band oscillations. These abnormalities are thought to reflect a deficiency in the synchronization of pyramidal cell activity that is dependent, in part, on gamma-aminobutyric acid (GABA) neurotransmission through GABA type A (GABA_A) receptors containing ₂ subunits. The authors conducted a proof-of-concept clinical trial designed to test the hypothesis that a novel compound with relatively selective agonist activity at GABA_A receptors containing ₂ subunits would improve cognitive function and gamma band oscillations in individuals with schizophrenia. METHOD: Participants were male subjects (N=15) with chronic schizophrenia who were randomly assigned to receive 4 weeks of treatment with the study drug MK-0777, a benzodiazepine-like agent with selective activity at GABA_A receptors containing ₂ or ₃ subunits, or a matched placebo in a double-blind fashion. Outcome measures were the Brief Psychiatric Rating Scale (BPRS), Repeatable Battery for the Assessment of Neuropsychological Status, three tests of working memory and/or cognitive control (N-back, AX Continuous Performance Test, and Preparing to Overcome Prepotency), and EEG measures of gamma band oscillations induced during the Preparing to Overcome Prepotency task. RESULTS: Compared with placebo, the MK-0777 compound was associated with improved performance on the N-back, AX Continuous Performance Test, and Preparing to Overcome Prepotency tasks. The compound was also associated with increased frontal gamma band power during the Preparing to Overcome Prepotency task. No effects of the MK-0777 compound were detected in BPRS or Repeatable Battery for the Assessment of Neuropsychological Status scores, with the exception of improvement on the Repeatable Battery for the Assessment of Neuropsychological Status delayed memory index. The MK-0777 agent was well-tolerated. CONCLUSIONS: These findings provide preliminary support for the hypothesis that enhanced GABA activity at ₂ subunit containing GABA_A receptors improves behavioral and electrophysiological measures of prefrontal function in individuals with schizophrenia.

This article has been cited by other articles:

				B. Wroblewska and D. A. Lewis Validating Novel Targets for Pharmacological Interventions in Schizophrenia Am J Psychiatry, July 1, 2009; 166(7): 753 - 756. [Full Text] [PDF]

				S. Akbarian Restoring GABAergic Signaling and Neuronal Synchrony in Schizophrenia Am J Psychiatry, December 1, 2008; 165(12): 1507 - 1509. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us